Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Background Psoriasis is a chronic inflammatory skin disease, which requires long‐term, safe
and effective treatment. Apremilast, a small‐molecule PDE 4 inhibitor, has been introduced …

The introduction of several new therapeutic agents, predominantly biologic therapies, has
transformed the management of moderate and severe psoriasis in recent years. A novel oral …

Background Real‐world data in patients with moderate psoriasis treated with apremilast is
limited. Objectives To evaluate the effectiveness and safety of apremilast in bio‐naïve …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Apremilast is a small molecule approved for the treatment of plaques psoriasis and adult
psoriatic arthritis. Pivotal studies have demonstrated short and long term efficacy and safety …

Background Experience in the use of apremilast in clinical practice complements the
information available from pivotal clinical trials. Materials and methods Following a review of …

Introduction Apremilast is approved for the treatment of psoriasis and psoriatic arthritis.
However, data on the efficacy and safety of apremilast in clinical practice are limited. We …

Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …

Background Little is known about the effectiveness and drug survival associated with
apremilast under real-world conditions. Objective To investigate the influence of patient and …